205 related articles for article (PubMed ID: 34295730)
1. A nomogram based on PI-RADS v2.1 and clinical indicators for predicting clinically significant prostate cancer in the transition zone.
Wei C; Pan P; Chen T; Zhang Y; Dai G; Tu J; Jiang Z; Zhao W; Shen J
Transl Androl Urol; 2021 Jun; 10(6):2435-2446. PubMed ID: 34295730
[TBL] [Abstract][Full Text] [Related]
2. The Role of PSA Density among PI-RADS v2.1 Categories to Avoid an Unnecessary Transition Zone Biopsy in Patients with PSA 4-20 ng/mL.
Wang ZB; Wei CG; Zhang YY; Pan P; Dai GC; Tu J; Shen JK
Biomed Res Int; 2021; 2021():3995789. PubMed ID: 34671673
[TBL] [Abstract][Full Text] [Related]
3. [Preliminary applicability evaluation of Prostate Imaging Reporting and Data System version 2 diagnostic score in 3.0T multi-parameters magnetic resonance imaging combined with prostate specific antigen density for prostate cancer].
Zuo MZ; Zhao WL; Wei CG; Zhang CY; Wen R; Gu YF; Li MJ; Zhang YY; Wu JF; Li X; Shen JK
Zhonghua Yi Xue Za Zhi; 2017 Dec; 97(47):3693-3698. PubMed ID: 29325321
[No Abstract] [Full Text] [Related]
4. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y
Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
[TBL] [Abstract][Full Text] [Related]
5. PI-RADS v2.1 Combined With Prostate-Specific Antigen Density for Detection of Prostate Cancer in Peripheral Zone.
Wen J; Tang T; Ji Y; Zhang Y
Front Oncol; 2022; 12():861928. PubMed ID: 35463349
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic Accuracy and Interobserver Agreement of PI-RADS Version 2 and Version 2.1 for the Detection of Transition Zone Prostate Cancers.
Wei CG; Zhang YY; Pan P; Chen T; Yu HC; Dai GC; Tu J; Yang S; Zhao WL; Shen JK
AJR Am J Roentgenol; 2021 May; 216(5):1247-1256. PubMed ID: 32755220
[No Abstract] [Full Text] [Related]
7. The diagnostic value of PI-RADS V1 and V2 using multiparametric MRI in transition zone prostate clinical cancer.
Wang X; Bao J; Ping X; Hu C; Hou J; Dong F; Guo L
Oncol Lett; 2018 Sep; 16(3):3201-3206. PubMed ID: 30127915
[TBL] [Abstract][Full Text] [Related]
8. Biparametric prostate MRI and clinical indicators predict clinically significant prostate cancer in men with "gray zone" PSA levels.
Wei CG; Chen T; Zhang YY; Pan P; Dai GC; Yu HC; Yang S; Jiang Z; Tu J; Lu ZH; Shen JK; Zhao WL
Eur J Radiol; 2020 Jun; 127():108977. PubMed ID: 32330776
[TBL] [Abstract][Full Text] [Related]
9. Using the prostate imaging reporting and data system version 2 (PI-RIDS v2) to detect prostate cancer can prevent unnecessary biopsies and invasive treatment.
Liu C; Liu SL; Wang ZX; Yu K; Feng CX; Ke Z; Wang L; Zeng XY
Asian J Androl; 2018; 20(5):459-464. PubMed ID: 29667616
[TBL] [Abstract][Full Text] [Related]
10. The potential of a nomogram combined PI-RADS v2.1 and contrast-enhanced ultrasound (CEUS) to reduce unnecessary biopsies in prostate cancer diagnostics.
Liu Y; Wang S; Xiang LH; Xu G; Dong L; Sun Y; Ye B; Zhang Y; Xu H
Br J Radiol; 2022 Sep; 95(1138):20220209. PubMed ID: 35877385
[TBL] [Abstract][Full Text] [Related]
11. Combining clinical and MRI data to manage PI-RADS 3 lesions and reduce excessive biopsy.
Yang S; Zhao W; Tan S; Zhang Y; Wei C; Chen T; Shen J
Transl Androl Urol; 2020 Jun; 9(3):1252-1261. PubMed ID: 32676408
[TBL] [Abstract][Full Text] [Related]
12. Modified Predictive Model and Nomogram by Incorporating Prebiopsy Biparametric Magnetic Resonance Imaging With Clinical Indicators for Prostate Biopsy Decision Making.
Pan JF; Su R; Cao JZ; Zhao ZY; Ren DW; Ye SZ; Huang RD; Tao ZL; Yu CL; Jiang JH; Ma Q
Front Oncol; 2021; 11():740868. PubMed ID: 34589437
[TBL] [Abstract][Full Text] [Related]
13. The prediction value of PI-RADS v2 score in high-grade Prostate Cancer: a multicenter retrospective study.
Chen S; Yang Y; Peng T; Yu X; Deng H; Guo Z
Int J Med Sci; 2020; 17(10):1366-1374. PubMed ID: 32624693
[No Abstract] [Full Text] [Related]
14. Prostate Cancer Detection with Multiparametric Magnetic Resonance Imaging: Prostate Imaging Reporting and Data System Version 1 versus Version 2.
Feng ZY; Wang L; Min XD; Wang SG; Wang GP; Cai J
Chin Med J (Engl); 2016 Oct; 129(20):2451-2459. PubMed ID: 27748338
[TBL] [Abstract][Full Text] [Related]
15. Construction and Validation of a Clinical Predictive Nomogram for Improving the Cancer Detection of Prostate Naive Biopsy Based on Chinese Multicenter Clinical Data.
Tao T; Wang C; Liu W; Yuan L; Ge Q; Zhang L; He B; Wang L; Wang L; Xiang C; Wang H; Chen S; Xiao J
Front Oncol; 2021; 11():811866. PubMed ID: 35127526
[TBL] [Abstract][Full Text] [Related]
16. PI-RADS v2.1 and PSAD for the prediction of clinically significant prostate cancer among patients with PSA levels of 4-10 ng/ml.
Wen J; Liu W; Shen X; Hu W
Sci Rep; 2024 Mar; 14(1):6570. PubMed ID: 38503972
[TBL] [Abstract][Full Text] [Related]
17. Evaluating the performance of PI-RADS v2 in the non-academic setting.
Jordan EJ; Fiske C; Zagoria RJ; Westphalen AC
Abdom Radiol (NY); 2017 Nov; 42(11):2725-2731. PubMed ID: 28451763
[TBL] [Abstract][Full Text] [Related]
18. Developing a nomogram based on multiparametric magnetic resonance imaging for forecasting high-grade prostate cancer to reduce unnecessary biopsies within the prostate-specific antigen gray zone.
Niu XK; Li J; Das SK; Xiong Y; Yang CB; Peng T
BMC Med Imaging; 2017 Feb; 17(1):11. PubMed ID: 28143433
[TBL] [Abstract][Full Text] [Related]
19. Combination of PI-RADS score and PSAD can improve the diagnostic accuracy of prostate cancer and reduce unnecessary prostate biopsies.
Wang C; Yuan L; Shen D; Zhang B; Wu B; Zhang P; Xiao J; Tao T
Front Oncol; 2022; 12():1024204. PubMed ID: 36465344
[TBL] [Abstract][Full Text] [Related]
20. Development and Validation of a Radiomics Nomogram for Predicting Clinically Significant Prostate Cancer in PI-RADS 3 Lesions.
Li T; Sun L; Li Q; Luo X; Luo M; Xie H; Wang P
Front Oncol; 2021; 11():825429. PubMed ID: 35155214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
